Cognitive and sleep peptides compared

Semax vs selank

Two short peptides from Russian research, with each figure tied to its own source.

Semax is a synthetic heptapeptide analog of the ACTH 4-10 fragment, and Selank is a heptapeptide analog of tuftsin.1,2,3 FDA's briefing states that Semax is a registered drug in Russia available as nasal drops, and a 2026 review writes that Semax and Selank are approved as drugs in Russia and not in the rest of the world.1,4

FDA's briefing found no pharmacokinetic study of Semax in humans by any route.1

FactSemaxSelank
What it isA synthetic heptapeptide analog of the ACTH 4-10 fragment, Met-Glu-His-Phe-Pro-Gly-Pro1A heptapeptide analog of tuftsin, Thr-Lys-Pro-Arg-Pro-Gly-Pro2,3
How it comesNasal drops of 0.1% and 1% in Russia; FDA found intranasal the only route in the human studies it reviewed1Given intranasally or intraperitoneally in animal studies8
Half-lifeNo human pharmacokinetic study found by FDA by any route; in vitro, quickly hydrolyzed in rat blood and brain tissue1A plasma study names its major breakdown products: TKPRP, TKP, RP and GP9
Studied doses
  • Stroke trial in 30 patients: the authors report the largest effect at 12 mg a day (moderate strokes) and 18 mg a day (severe), courses of 5 and 10 days10
  • Peptic ulcer report: 1% solution, 2 to 4 drops 3 times a day for 10 days, intranasal11
  • Patient report: Selank in 30 patients against medazepam in 3212
  • Mice: 300 µg/kg a day for 5 days8
StatusA registered drug in Russia; not a component of an FDA-approved drug. FDA's briefing names immunogenicity concerns by injection and a risk of bleeding1Approved in Russia for mild anxiety, not elsewhere, per a review that also writes WADA prohibits both as S2 or unapproved substances4

Get the app

Contents6
  1. 1Studies that included both
  2. 2How they differ
  3. 3Logged in Milligram
  4. 4What is not known
  5. 5References
  6. 6Related pages

Last reviewed . Sources are listed below.

Studies that included both

A 2020 imaging study of 52 healthy participants ran resting-state scans before and 5 and 20 minutes after an injection of Selank, Semax or placebo; the abstract does not name the route.5 The authors report differences in connectivity between the right amygdala and the right temporal cortex, with general and specific effects of Selank and Semax.5

A 2001 laboratory study found that both inhibit enkephalin-degrading enzymes of human serum, with an IC50 of 10 microM for Semax and 20 microM for Selank.6

How they differ

FDA's briefing describes the ACTH 4-10 fragment behind Semax as devoid of the hormonal corticotropic and melanotropic properties of ACTH.1 Laboratory work reports that Selank affects GABA binding as a positive allosteric modulator, and other authors word this as one possible mechanism.2,3

Logged in Milligram

  • Semax: 3% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
  • Selank: Too few people logged it to show a share.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

FDA's reviewers did not consider Russian-language references on cerebral ischemia, because the full references were not available in English.1 The briefing concludes that a balancing of the criteria weighs against placing semax or semax acetate on the 503A bulks list.1 On its list of category 2 substances whose nominations were withdrawn, FDA states that compounded selank acetate may pose a risk of immunogenicity for certain routes, and that it lacks important information on safety issues raised by selank acetate in humans.7

References

  1. US Food and Drug Administration. Evaluation of Semax-related bulk drug substances (Semax (free base) and Semax acetate) for inclusion on the 503A bulk drug substances list. FDA briefing document, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated 5/11/2026). Regulator briefing document, 2026. fda.gov
  2. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Laboratory study, 2018. PMID 30255741
  3. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Animal study, 2016. PMC4757669
  4. Renke G, Chinellato L. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives. Review, 2026. PMC13164565
  5. Panikratova YR, Lebedeva IS, Sokolov OY, et al. Functional Connectomic Approach to Studying Selank and Semax Effects. Imaging study, 2020. PMID 32342318
  6. Kost NV, Sokolov OIu, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Laboratory study, 2001. PMID 11443939
  7. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 22 April 2026). Regulator page, 2026. fda.gov
  8. Vasil'eva EV, Kondrakhin EA, Salimov RM, et al. Comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice. Animal study, 2016. PMID 29787664
  9. Zolotarev IuA, Dadaian AK, Dolotov OV, et al. Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation. Laboratory study, 2006. PMID 16637290
  10. Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV. [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Journal record (PubMed), 1997. PMID 11517472
  11. Ivanikov IO, Brekhova ME, Samonina GE, Myasoedov NF, Ashmarin IP. Therapy of peptic ulcer with semax peptide. Journal record (PubMed), 2002. PMID 12459874
  12. Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Randomised trial, 2008. PMID 18454096